choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Renal Cell Carcinoma Drugs

Renal Cell Carcinoma Drugs Newsletter
  • Korea lags behind global standards in kidney cancer treatment, expert warns 19 Jun 2025 09:18 GMT

    … tried. Currently, cytotoxic anticancer drugs are only used for a … kidney cancer called collecting duct renal cell carcinoma. Recently, targeted therapies, including … Park emphasized that kidney cancer drug treatment has improved significantly, but domestic …

  • Navigating Second-Line RCC Treatment With Guidelines and Trial Data 18 Jun 2025 08:20 GMT

    Second-line treatment for clear cell renal cell carcinoma (RCC) remains challenging due to a … me, it's a drug that has significant activity. I … tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor …

  • George Shares Takeaways From IO Trials and AE Management in Pretreated RCC 18 Jun 2025 18:05 GMT

    … mitigated with drug holds or other medications. GEORGE: … lot of other drugs like nivolumab and … renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment … monotherapy in patients with renal cell carcinoma (RCC) following 1 or …

  • KEYNOTE-564: Favorable Long-Term Safety With Adjuvant Pembrolizumab in RCC 18 Jun 2025 18:04 GMT

    … of adjuvant pembrolizumab for the treatment of renal cell carcinoma (RCC). Over the past 3 … earlier recognition and more prompt treatment of these toxicities, an … pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). J Clin …

  • GI Innovation wins US patent for dual-action IL-2 therapy targeting cold tumors 19 Jun 2025 07:10 GMT

    … exclusive rights to the drug’s bispecific fusion … or cytotoxic lymphocytes.  The drug is designed to revive … NSCLC, pancreatic cancer, and renal cell carcinoma at Severance Hospital, Samsung … combination. Importantly, the treatment did not trigger cytokine …

  • Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer? 19 Jun 2025 05:07 GMT

    … s top-selling cancer drug, pembrolizumab (Keytruda; Merck … Inventory management, updating treatment plans, and educating staff … seen this with other drugs,” notably rituximab, Soefje … or metastatic clear cell renal cell carcinoma (ccRCC): pharmacokinetics (PK …

  • Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC 14 Jun 2025 16:50 GMT

    … with previously untreated stage 4 renal cell carcinoma (RCC). Initial findings from an expansion … The most common reason for treatment discontinuation was radiographic progression, reported … nivolumab/relatlimab arm. Treatment-emergent AEs of any grade …

  • Dr Chehrazi-Raffle on the Safety of Second-Line Tivozanib With/Without Nivolumab in RCC 14 Jun 2025 06:53 GMT

    … ) in patients with metastatic renal cell carcinoma (RCC), as well as clinical … nivolumab as second-line treatment. Findings presented at the … -line setting for metastatic RCC, Chehrazi-Raffle emphasized. … alone in patients with RCC. In the subgroup analysis …

  • American Kidney Fund Launches Kidney Cancer Education Campaign 18 Jun 2025 13:13 GMT

    … adults is renal cell carcinoma (RCC), which is further divided into clear cell renal cell carcinoma (ccRCC … genetic diseases, and long-term treatment for kidney failure.  ### About …

  • Zanzalintinib Triplet Combo Under Investigation in Kidney Cancer Subgroups 17 Jun 2025 22:09 GMT

    treatment option worth exploring in patients with previously untreated clear cell renal cell carcinoma … doses or temporarily holding the medications. One notable part of the … we continue searching for new drugs and regimens for patients with …

Satisfied with the content?

Continue to create your account.